Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: A multicenter randomized study in Japan

Blood

Volumn 110, Issue 6, 2007, Pages 1756-1761

  Teramura, Masanao ^a   Kimura, Akiro ^b   Iwase, Satsuki ^c   Yonemura, Yuji ^d   Nakao, Shinji ^e   Urabe, Akio ^f   Omine, Mitsuhiro ^g   Mizoguchi, Hideaki ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c Jikei University Katsushika Medical Center   (Japan)

^d KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^e KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^f NTT CORPORATION   (Japan)

^g SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; HEMOGLOBIN; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THYMOCYTE ANTIBODY;

ADULT; AGED; ALLERGIC REACTION; APLASTIC ANEMIA; ARTICLE; BACTEREMIA; CELLULITIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG DOSE REDUCTION; FEMALE; FEVER; FUNGEMIA; GENITAL TRACT INFECTION; GINGIVITIS; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INTESTINE INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOSIS; NEUTROPHIL COUNT; PNEUMONIA; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RETICULOCYTE COUNT; SERUM SICKNESS; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 34548840525     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-11-050526     Document Type: Article

References (31)

1. Gluckman E, Esperou-Bourdeau H, Baruchel A, et al. Multicenter randomized study comparing cyclosporine-A alone and antithymocyte globulin with prednisone for treatment of severe aplastic anemia. Blood. 1992;79:2540-2546.
2. Frickhofen N, Kaltwasser JP, Schrezenmeier H, et al. Treatment of aplastic anemia with antithymocyte globulin and methylprednisolone with or without cyclosporine. N Engl J Med. 1991;324:1297-1304.
3. Marsh J, Schrezenmeier H, Marin P, et al. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. Blood. 1999;93:2191-2195.
4. Ikebuchi K, Clark SC, Ihle JN, Souza LM, Ogawa M. Granulocyte colony-stimulating factor enhances interleukin 3-dependent proliferation of multipotential hemopoietic progenitors. Proc Natl Acad Sci U S A. 1998;85:3445-3449.
5. Kojima S, Fukuda M, Miyajima Y, Matsuyama T, Horibe K. Treatment of aplastic anemia in children with recombinant human granulocyte colony-stimulating factor. Blood. 1991;77:937-941.
6. Sonoda Y, Ohno Y, Fujii H, et al. Multilineage response in aplastic anemia patients following longterm administration of filgrastim (recombinant human granulocyte colony stimulating factor). Stem Cells. 1993;11:543-554.
7. Imashuku S, Akiyama Y, Nakajima F, Hibi S, Oguni T, Koike M. Multilineage response to G-CSF in paediatric aplastic anaemia. Lancet. 1994;344:1236-1137.
8. Bacigalupo A, Broccia G, Corda G, et al. Antilymphocyte globulin, cyclosporin, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA): a pilot study of the EBMT SAA Working Party. Blood. 1995;85:1348-1353.
9. Tichelli A, Gratwohl A, Wursch A, Nissen C, Speck B. Late haematological complications in severe aplastic anaemia. Br J Haematol. 1988;69:413-418.
10. DePlanque MM, Bacigalupo A, Wursch A, et al. Long-term follow-up of severe aplastic anaemia patients treated with antithymocyte globulin: Severe Aplastic Anaemia Working Party of the European Cooperative Group for Bone Marrow Transplantation (EBMT). Br J Haematol. 1989;73:121-126.
11. Socie G, Amar MH, Bacigalupo A, et al. Malignant tumors occurring after treatment of aplastic anemia. N Engl J Med. 1993;329:1152-1157.
12. Kojima S, Tsuchida M, Matsuyama T. Myelodysplasia and leukemia after treatment of aplastic anemia with G-CSF. N Engl J Med. 1992;326:1294-1295.
13. Imashuku S, Hibi S, Kataoka-Morimoto Y, et al. Myelodysplasia and acute myeloid leukaemia in cases of aplastic anaemia and congenital neutropenia following G-CSF administration. Br J Haematol. 1995;89:188-190.
14. Kojima S, Hibi S, Kosaka Y, et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood. 2000;96:2049-2054.
15. Gluckman E, Rokicka-Milewska R, Hann I, et al. Results and follow-up of a phase III randomized study of recombinant human-granulocyte stimulating factor as support for immunosuppressive therapy in patients with severe aplastic anaemia. Br J Haematol. 2002;119:1075-1082.
16. Camitta BM, Thomas ED, Nathan DG, et al. Severe aplastic anemia:a prospective study of the effect of early marrow transplantation on acute mortality. Blood. 1976;48:63-70.
17. Kojima S, Matsuyama T, Miyazaki T, et al. Treatment of aplastic anemia with KRN8601 (rhGCSF). Jpn J Clin Hematol. 1990;31:929-936.
18. Asano S, Hirashima K, Yoshida Y, et al. Clinical effect of recombinant human granulocyte colony-stimulating factor on aplastic anemia. Jpn J Clin Hematol. 1990;31:1456-1462.
19. Camitta BM. What is the definition of cure for aplastic anemia? Acta Haematol. 2000;103:16-18.
20. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207-214.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
22. Scopes J, Daly S, Atkinson R, Ball SE, Gordon-Smith EC, Gibson FM. Aplastic anemia: evidence for dysfunctional bone marrow progenitor cells and the corrective effect of granulocyte colony-stimulating factor in vitro. Blood. 1996;87:3179-3185.
23. Schrezenmeier H, Marin P, Raghavachar A, et al. Relapse of aplastic anaemia after immunosuppressive treatment: a report from the European Bone Marrow Transplantation Group SAA Working Party. Br J Haematol. 1993;85:371-377.
24. Socie G, Rosenfeld S, Frickhofen N, Gluckman E, Tichelli A. Late clonal diseases of treated aplastic anemia. Semin Hematol. 2000;37:91-101.
25. Kaito K, Kobayashi M, Katayama T, et al. Long-term administration of G-CSF for aplastic anaemia is closely related to the early evolution of monosomy 7 MDS in adults. Br J Haematol. 1998;103:297-303.
26. Kojima S, Ohara A, Tsuchida M, et al. Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children. Blood. 2002;100:786-790.
27. Socie G, Mary JY, Schrezenmeier H, et al. Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT). Blood. 2007;109:2794-2796.
28. Locasciulli A, Arcese W, Locatelli F, Di Bona E, Bacigalupo A. Italian Aplastic Anaemia Study Group. Treatment of aplastic anaemia with granulocyte-colony stimulating factor and risk of malignancy. Lancet. 2001;357:43-44.
29. Sloand EM, Yong AS, Ramkissoon S, et al. Granulocyte colony-stimulating factor preferentially stimulates proliferation of monosomy 7 cells bearing the isoform IV receptor. Proc Natl Acad Sci U S A. 2006;103:14483-14488.
30. Mikhailova N, Sessarego M, Fugazza G, et al. Cytogenetic abnormalities in patients with severe aplastic anemia. Haematologica. 1996;81:418-422.
31. Geary CG, Harrison CJ, Philpott NJ, Hows JM, Gordon-Smith EC, Marsh JCW. Abnormal cytogenetic clones in patients with aplastic anaemia: response to immunosuppressive therapy. Br J Haematol. 1999;104:271-274.